Inhibikase Therapeutics (IKT) Other financing activities (2020 - 2025)

Inhibikase Therapeutics (IKT) has 4 years of Other financing activities data on file, last reported at $562915.0 in Q4 2025.

• On a quarterly basis, Other financing activities changed N/A year-over-year to $562915.0 in Q4 2025; TTM through Dec 2025 was $813847.0, a N/A change from a year earlier, with the FY2025 full-year figure at $845468.0, changed N/A from the prior year.
• Other financing activities for Q4 2025 stood at $562915.0, up from $250932.0 in the prior quarter.
• Over the last five years, Other financing activities for IKT reached as high as $41.1 million in Q4 2021 and fell as low as $34357.0 in Q2 2021.
• Historically, Other financing activities has averaged $7.0 million across 3 years, with a median of $147537.5 in 2021.
• On a YoY basis, Other financing activities climbed as much as 177.66% in 2021 and fell as far as 177.66% in 2021.
• Year by year, Other financing activities stood at $41.1 million in 2021, then tumbled by 99.89% to $44142.0 in 2022, then jumped by 1175.24% to $562915.0 in 2025.
• Per Business Quant data, the three most recent Other financing activities figures were $562915.0 in Q4 2025, $250932.0 in Q3 2025, and $44142.0 in Q1 2022.